BLUE Stock Overview
A biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
bluebird bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.20 |
52 Week High | US$5.53 |
52 Week Low | US$0.84 |
Beta | 0.85 |
11 Month Change | 26.61% |
3 Month Change | 30.04% |
1 Year Change | -67.83% |
33 Year Change | -95.32% |
5 Year Change | -99.06% |
Change since IPO | -95.54% |
Recent News & Updates
Recent updates
bluebird bio's Flight Through Financial Fog And Fierce Rivals
Jun 27bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval
Feb 07bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success
Dec 12Shareholder Returns
BLUE | US Biotechs | US Market | |
---|---|---|---|
7D | 4.3% | 3.4% | -2.4% |
1Y | -67.8% | 17.1% | 17.5% |
Return vs Industry: BLUE underperformed the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: BLUE underperformed the US Market which returned 17.2% over the past year.
Price Volatility
BLUE volatility | |
---|---|
BLUE Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BLUE's share price has been volatile over the past 3 months.
Volatility Over Time: BLUE's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 323 | Andrew Obenshain | www.bluebirdbio.com |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
BLUE fundamental statistics | |
---|---|
Market cap | US$221.65m |
Earnings (TTM) | -US$91.17m |
Revenue (TTM) | US$21.73m |
10.6x
P/S Ratio-2.5x
P/E RatioIs BLUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BLUE income statement (TTM) | |
---|---|
Revenue | US$21.73m |
Cost of Revenue | US$203.70m |
Gross Profit | -US$181.97m |
Other Expenses | -US$90.80m |
Earnings | -US$91.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.47 |
Gross Margin | -837.57% |
Net Profit Margin | -419.62% |
Debt/Equity Ratio | 0% |
How did BLUE perform over the long term?
See historical performance and comparison